Skip to main content
Top
Published in: Drugs & Aging 8/2009

01-08-2009 | Original Research Article

Impact of Residential Medication Management Reviews on Drug Burden Index in Aged-Care Homes

A Retrospective Analysis

Authors: Mr Prasad S. Nishtala, Sarah N. Hilmer, Andrew J. McLachlan, Paul J. Hannan, Timothy F. Chen

Published in: Drugs & Aging | Issue 8/2009

Login to get access

Abstract

Background

The Drug Burden Index (DBI) is an evidence-based tool that associates medication exposure with functional outcomes in older people. Accredited clinical pharmacists performing medication reviews could consider including the DBI in their medication reviews to optimize prescribing in older people.

Objective

To examine the impact of residential medication management reviews (RMMRs) performed by accredited clinical pharmacists on DBI in older people living in aged-care homes.

Methods

A retrospective analysis was performed of a random sample of 500 de-identified RMMR reports from residents aged (mean±SD) 84±9.0 years who had medication reviews conducted by ten accredited clinical pharmacists from 1 January 2008 through 30 June 2008. The data on medication use were collected over 8 months across 62 aged-care homes. DBI scores were calculated at baseline, after the recommendations had been made by the pharmacist and after uptake of pharmacist recommendations by the general practitioner (GP).

Results

A statistically significant decrease (p<0.001) in median DBI score was observed as a result of uptake of pharmacist recommendations by the GP. GPs were more likely to take up recommendations made by pharmacists that resulted in a decrease in DBI score than recommendations that resulted in an increase in DBI score (60.7% vs 34.6%, respectively). The mean decrease in DBI as a result of pharmacist recommendations was 0.12 (95% CI 0.09, 0.14) representing a 20% decrease in mean baseline DBI for residents. When GPs implemented pharmacists’ recommendations, DBI decreased by a mean of 12% from baseline (mean decrease 0.07; 95% CI 0.05, 0.08). Most of the recommendations proposed by the pharmacists involved withdrawing benzodiazepines or reducing antipsychotic drug dosage.

Conclusions

This is the first study in which DBI has been used as a tool to evaluate the impact of RMMRs conducted by accredited clinical pharmacists. The study demonstrates that pharmacist-conducted medication reviews can reduce prescribing of sedative and anticholinergic drugs in older people, resulting in a significant decrease in the DBI score.
Appendix
Available only for authorised users
Literature
1.
go back to reference McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004; 56(2): 163–84PubMedCrossRef McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004; 56(2): 163–84PubMedCrossRef
2.
go back to reference Hilmer SN, McLachlan AJ, Le Couteur DG. Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol 2007; 21(3): 217–30PubMedCrossRef Hilmer SN, McLachlan AJ, Le Couteur DG. Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol 2007; 21(3): 217–30PubMedCrossRef
3.
go back to reference Hilmer SN, Gnjidic D. The effects of polypharmacy in older adults. Clin Pharmacol Ther 2009; 85(1): 86–8PubMedCrossRef Hilmer SN, Gnjidic D. The effects of polypharmacy in older adults. Clin Pharmacol Ther 2009; 85(1): 86–8PubMedCrossRef
4.
go back to reference Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341(27): 2061–7PubMedCrossRef Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341(27): 2061–7PubMedCrossRef
5.
go back to reference Wenger NK. Enrollment and maintenance of elderly patients in cardiovascular clinical trials. Am J Geriatr Cardiol 2006; 15(6): 352–6PubMedCrossRef Wenger NK. Enrollment and maintenance of elderly patients in cardiovascular clinical trials. Am J Geriatr Cardiol 2006; 15(6): 352–6PubMedCrossRef
6.
go back to reference Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003; 163(22): 2716–24PubMedCrossRef Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003; 163(22): 2716–24PubMedCrossRef
7.
go back to reference Basger BJ, Chen TF, Moles RJ. Inappropriate medication use and prescribing indicators in elderly Australians: development of a prescribing indicators tool. Drugs Aging 2008; 25(9): 777–93PubMedCrossRef Basger BJ, Chen TF, Moles RJ. Inappropriate medication use and prescribing indicators in elderly Australians: development of a prescribing indicators tool. Drugs Aging 2008; 25(9): 777–93PubMedCrossRef
8.
go back to reference Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005; 294(6): 716–24PubMedCrossRef Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005; 294(6): 716–24PubMedCrossRef
9.
go back to reference Guralnik JM, Ferrucci L, Simonsick EM, et al. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med 1995; 332(9): 556–61PubMedCrossRef Guralnik JM, Ferrucci L, Simonsick EM, et al. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med 1995; 332(9): 556–61PubMedCrossRef
10.
go back to reference Terry DF, Sebastiani P, Andersen SL, et al. Disentangling the roles of disability and morbidity in survival to exceptional old age. Arch Intern Med 2008; 168(3): 277–83PubMedCrossRef Terry DF, Sebastiani P, Andersen SL, et al. Disentangling the roles of disability and morbidity in survival to exceptional old age. Arch Intern Med 2008; 168(3): 277–83PubMedCrossRef
11.
go back to reference Gray SL, LaCroix AZ, Hanlon JT, et al. Benzodiazepine use and physical disability in community-dwelling older adults. J Am Geriatr Soc 2006; 54(2): 224–30PubMedCrossRef Gray SL, LaCroix AZ, Hanlon JT, et al. Benzodiazepine use and physical disability in community-dwelling older adults. J Am Geriatr Soc 2006; 54(2): 224–30PubMedCrossRef
12.
go back to reference Mulsant BH, Pollock BG, Kirshner M, et al. Serum antic-holinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry 2003; 60(2): 198–203PubMedCrossRef Mulsant BH, Pollock BG, Kirshner M, et al. Serum antic-holinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry 2003; 60(2): 198–203PubMedCrossRef
13.
go back to reference Hilmer SN, Mager DE, Simonsick EM, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med 2007; 167(8): 781–7PubMedCrossRef Hilmer SN, Mager DE, Simonsick EM, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med 2007; 167(8): 781–7PubMedCrossRef
14.
go back to reference Iyer S, Naganathan V, McLachlan AJ, et al. Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs Aging 2008; 25(12): 1021–31PubMedCrossRef Iyer S, Naganathan V, McLachlan AJ, et al. Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs Aging 2008; 25(12): 1021–31PubMedCrossRef
15.
go back to reference Landi F, Russo A, Liperoti R, et al. Anticholinergic drugs and physical function among frail elderly population. Clin Pharmacol Ther 2007; 81(2): 235–41PubMedCrossRef Landi F, Russo A, Liperoti R, et al. Anticholinergic drugs and physical function among frail elderly population. Clin Pharmacol Ther 2007; 81(2): 235–41PubMedCrossRef
16.
go back to reference Cao YJ, Mager DE, Simonsick EM, et al. Physical and cognitive performance and burden of anticholinergics, sedatives, and ACE inhibitors in older women. Clin Pharmacol Ther 2008; 83(3): 422–9PubMedCrossRef Cao YJ, Mager DE, Simonsick EM, et al. Physical and cognitive performance and burden of anticholinergics, sedatives, and ACE inhibitors in older women. Clin Pharmacol Ther 2008; 83(3): 422–9PubMedCrossRef
17.
go back to reference Gnjidic D, Cumming RG, Le Couteur DG, et al. Drug burden index and physical function in older Australian men. Br J Clin Pharmacol 2009 Jul; 68(1): 97–105PubMedCrossRef Gnjidic D, Cumming RG, Le Couteur DG, et al. Drug burden index and physical function in older Australian men. Br J Clin Pharmacol 2009 Jul; 68(1): 97–105PubMedCrossRef
18.
go back to reference Rosano C, Simonsick EM, Harris TB, et al. Association between physical and cognitive function in healthy elderly: the Health, Aging and Body Composition study. Neuro-epidemiology 2005; 24(1–2): 8–14 Rosano C, Simonsick EM, Harris TB, et al. Association between physical and cognitive function in healthy elderly: the Health, Aging and Body Composition study. Neuro-epidemiology 2005; 24(1–2): 8–14
19.
go back to reference Campbell AJ, Robertson MC, Gardner MM, et al. Psychotropic medication withdrawal and a home-based exercise program to prevent falls: a randomized, controlled trial. J Am Geriatr Soc 1999; 47(7): 850–3PubMed Campbell AJ, Robertson MC, Gardner MM, et al. Psychotropic medication withdrawal and a home-based exercise program to prevent falls: a randomized, controlled trial. J Am Geriatr Soc 1999; 47(7): 850–3PubMed
20.
go back to reference van der Velde N, Stricker BH, Pols HA, et al. Withdrawal of fall-risk-increasing drugs in older persons: effect on mobility test outcomes. Drugs Aging 2007; 24(8): 691–9PubMedCrossRef van der Velde N, Stricker BH, Pols HA, et al. Withdrawal of fall-risk-increasing drugs in older persons: effect on mobility test outcomes. Drugs Aging 2007; 24(8): 691–9PubMedCrossRef
21.
go back to reference Ballard C, Hanney ML, Theodoulou M, et al. The Dementia Antipsychotic Withdrawal Trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 2009; 8(2): 151–7PubMedCrossRef Ballard C, Hanney ML, Theodoulou M, et al. The Dementia Antipsychotic Withdrawal Trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 2009; 8(2): 151–7PubMedCrossRef
22.
go back to reference Roberts MS, Stokes JA, King MA, et al. Outcomes of a randomized controlled trial of a clinical pharmacy intervention in 52 nursing homes. Br J Clin Pharmacol 2001; 51(3): 257–65PubMedCrossRef Roberts MS, Stokes JA, King MA, et al. Outcomes of a randomized controlled trial of a clinical pharmacy intervention in 52 nursing homes. Br J Clin Pharmacol 2001; 51(3): 257–65PubMedCrossRef
24.
go back to reference Nissen D. editor. Mosby’s drug consult. St Louis (MO): Mosby Inc., 2004 Nissen D. editor. Mosby’s drug consult. St Louis (MO): Mosby Inc., 2004
25.
go back to reference Duplay D. editor. Physicians’ Desk Reference. 58th ed. Montvale (NJ): Thomson PDR, 2004 Duplay D. editor. Physicians’ Desk Reference. 58th ed. Montvale (NJ): Thomson PDR, 2004
26.
go back to reference Tallarida RJ. Drug synergism: its detection and applications. J Pharmacol Exp Ther 2001; 298(3): 865–72PubMed Tallarida RJ. Drug synergism: its detection and applications. J Pharmacol Exp Ther 2001; 298(3): 865–72PubMed
27.
go back to reference Nishtala PS, McLachlan AJ, Bell JS, et al. Psychotropic prescribing in long-term care facilities: impact of medication reviews and educational interventions. Am J Geriatr Psychiatry 2008; 16(8): 621–32PubMedCrossRef Nishtala PS, McLachlan AJ, Bell JS, et al. Psychotropic prescribing in long-term care facilities: impact of medication reviews and educational interventions. Am J Geriatr Psychiatry 2008; 16(8): 621–32PubMedCrossRef
28.
go back to reference Cumming RG, Le Couteur DG. Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs 2003; 17(11): 825–37PubMedCrossRef Cumming RG, Le Couteur DG. Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs 2003; 17(11): 825–37PubMedCrossRef
29.
go back to reference Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987; 316(7): 363–9PubMedCrossRef Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987; 316(7): 363–9PubMedCrossRef
30.
go back to reference Mort JR, Aparasu RR. Prescribing of psychotropics in the elderly: why is it so often inappropriate? CNS Drugs 2002; 16(2): 99–109PubMedCrossRef Mort JR, Aparasu RR. Prescribing of psychotropics in the elderly: why is it so often inappropriate? CNS Drugs 2002; 16(2): 99–109PubMedCrossRef
31.
go back to reference Rochon PA, Normand SL, Gomes T, et al. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med 2008; 168(10): 1090–6PubMedCrossRef Rochon PA, Normand SL, Gomes T, et al. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med 2008; 168(10): 1090–6PubMedCrossRef
32.
go back to reference Ancelin ML, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006; 332(7539): 455–9PubMedCrossRef Ancelin ML, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006; 332(7539): 455–9PubMedCrossRef
33.
go back to reference Bottiggi KA, Salazar JC, Yu L, et al. Long-term cognitive impact of anticholinergic medications in older adults. Am J Geriatr Psychiatry 2006; 14(11): 980–4PubMedCrossRef Bottiggi KA, Salazar JC, Yu L, et al. Long-term cognitive impact of anticholinergic medications in older adults. Am J Geriatr Psychiatry 2006; 14(11): 980–4PubMedCrossRef
34.
go back to reference Hutt E, Pepper GA, Vojir C, et al. Assessing the appropriateness of pain medication prescribing practices in nursing homes. J Am Geriatr Soc 2006; 54(2): 231–9PubMedCrossRef Hutt E, Pepper GA, Vojir C, et al. Assessing the appropriateness of pain medication prescribing practices in nursing homes. J Am Geriatr Soc 2006; 54(2): 231–9PubMedCrossRef
35.
go back to reference Sorensen L, Stokes JA, Purdie DM, et al. Medication reviews in the community: results of a randomized, controlled effectiveness trial. Br J Clin Pharmacol 2004; 58(6): 648–64PubMedCrossRef Sorensen L, Stokes JA, Purdie DM, et al. Medication reviews in the community: results of a randomized, controlled effectiveness trial. Br J Clin Pharmacol 2004; 58(6): 648–64PubMedCrossRef
36.
go back to reference Patel HR, Pruchnicki MC, Hall LE. Assessment for chronic kidney disease service in high-risk patients at community health clinics. Ann Pharmacother 2005; 39(1): 22–7PubMed Patel HR, Pruchnicki MC, Hall LE. Assessment for chronic kidney disease service in high-risk patients at community health clinics. Ann Pharmacother 2005; 39(1): 22–7PubMed
37.
go back to reference Krska J, Cromarty JA, Arris F, et al. Pharmacist-led medication review in patients over 65: a randomized, controlled trial in primary care. Age Ageing 2001; 30(3): 205–11PubMedCrossRef Krska J, Cromarty JA, Arris F, et al. Pharmacist-led medication review in patients over 65: a randomized, controlled trial in primary care. Age Ageing 2001; 30(3): 205–11PubMedCrossRef
38.
go back to reference O’Dell KM, Kucukarslan SN. Impact of the clinical pharmacist on readmission in patients with acute coronary syndrome. Ann Pharmacother 2005; 39(9): 1423–7PubMedCrossRef O’Dell KM, Kucukarslan SN. Impact of the clinical pharmacist on readmission in patients with acute coronary syndrome. Ann Pharmacother 2005; 39(9): 1423–7PubMedCrossRef
39.
go back to reference Sellors J, Kaczorowski J, Sellors C, et al. A randomized controlled trial of a pharmacist consultation program for family physicians and their elderly patients. CMAJ 2003; 169(1): 17–22PubMed Sellors J, Kaczorowski J, Sellors C, et al. A randomized controlled trial of a pharmacist consultation program for family physicians and their elderly patients. CMAJ 2003; 169(1): 17–22PubMed
40.
go back to reference Schmidt IK, Claesson CB, Westerholm B, et al. Physician and staff assessments of drug interventions and outcomes in Swedish nursing homes. Ann Pharmacother 1998; 32(1): 27–32PubMedCrossRef Schmidt IK, Claesson CB, Westerholm B, et al. Physician and staff assessments of drug interventions and outcomes in Swedish nursing homes. Ann Pharmacother 1998; 32(1): 27–32PubMedCrossRef
41.
go back to reference Department of Health and Ageing, Commonwealth of Australia. A literature review and description of the regulatory framework. 2005 Nov [online]. Available from URL: http://www.health.gov.au [Accessed 2008 Nov 28] Department of Health and Ageing, Commonwealth of Australia. A literature review and description of the regulatory framework. 2005 Nov [online]. Available from URL: http://​www.​health.​gov.​au [Accessed 2008 Nov 28]
Metadata
Title
Impact of Residential Medication Management Reviews on Drug Burden Index in Aged-Care Homes
A Retrospective Analysis
Authors
Mr Prasad S. Nishtala
Sarah N. Hilmer
Andrew J. McLachlan
Paul J. Hannan
Timothy F. Chen
Publication date
01-08-2009
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 8/2009
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/11316440-000000000-00000

Other articles of this Issue 8/2009

Drugs & Aging 8/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.